Saturday, October 29, 2016: 8:30 AM-10:00 AM
Room: 391-392
Learning Objectives:
At the conclusion of this session, participants will be able to:
- recognize indications of antiviral treatment for hepatitis B and C in immunocompromised hosts
- describe antiviral management options for hepatitis virus infections in immunocompromised hosts
- discuss strategies for preventing hepatitis B and C recurrence after organ and tissue transplantation
Target Audience: Academicians, Clinicians, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Members-in-training, Microbiologists, Nurses, Pharmacists, Researchers, Scientists, Vaccinologists
Tracks: Investigative ID, Epidemiology and Infection Control, Adult ID
Moderators:
Raymund R. Razonable, MD, FIDSA, Mayo Clinic
and
David Van Duin, MD, PhD, University of North Carolina
Presentations:
CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™
ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE
ACPE Number: 0221-9999-16-283-L01-P
Disclosures:
R. R. Razonable,
None
tetraphase: Scientific Advisor , Consulting fee
actavis: Scientific Advisor , Consulting fee
medimmune: Scientific Advisor , Consulting fee
Sanofi-Pasteur: Scientific Advisor , Consulting fee
scynexis: Investigator , Research support
steris: Grant Investigator , Research grant
See more of: Symposium